# NCT04526691 (NCT04526691)

> Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04526691
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Advanced or Metastatic NSCLC
- Interventions: Datopotamab deruxtecan; KEYTRUDA®; Carboplatin; Cisplatin
- Enrollment: 145
- Primary outcome: Number of Participants with Dose-limiting Toxicities (DLTs) and Treatment-emergent Adverse Events (TEAEs)

## Commentary we found

- X threads: 35
- Podcasts: 19
- YouTube: 10

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04526691

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04526691", "email": "<work email>"}; the inbox owner confirms by the emailed link.